A series of reassortants was isolated from coinfection of cell cultures with a wild-type animal rotavirus and a "noncultivatable" human rotavirus. Wild-type bovine rotavirus (UK strain) was reassorted with human rotavirus strains D, DS-1, and P; wild-type rhesus rotavirus was reassorted with human rotavirus strains D and DS-1. The D, DS-1, and P strains represent human rotavirus serotypes 1, 2, and 3, respectively. Monospecific antiserum (to bovine rotavirus, NCDV strain) or a set of monoclonal antibodies to the major outer capsid neutralization glycoprotein, VP7 (of the rhesus rotavirus), was used to select for reassortants with human rotavirus neutralization specificity. This selection technique yielded many reassortants which received only the gene segment coding for the major neutralization protein from the human rotavirus parent, whereas the remaining genes were derived from the animal rotavirus parent. Single human rotavirus gene substitution reassortants of this sort represent potential live vaccine strains.
Rotaviruses, newly classified members of the reoviridae family, are an important cause of infantile diarrhea in a wide variety of mammalian species including humans. Approximately 40% of severe pediatric diarrheal disease in most parts of the world is caused by rotaviruses (11) . Since diarrheal disease is the leading cause of mortality in infants and young children in developing countries, and it is likely that rotaviruses are responsible for a considerable proportion of such fatalities, the development of a rotavirus vaccine represents an important public health priority. Various approaches to this goal have been considered, and two of these, the use of an attenuated human or an animal rotavirus strain as a candidate vaccine, have already been tested in humans (15, 16, 19 ). Animal rotavirus candidate vaccines include bovine rotavirus NCDV and UK strains and rhesus rotavirus (RRV) strain MMU 18006. Vesikari et al. have shown that oral administration of bovine rotavirus NCDV strain induced resistance in infants and young children against moderate or severe diarrheal illness caused by human rotavirus (15, 16) . In preliminary studies, bovine rotavirus UK strain and RRV appear to be attenuated. Wyatt et al. administered the UK strain of bovine rotavirus to 11 adult volunteers, 2 with high and 9 with low levels of serum neutralizing antibodies. None of these individuals developed a diarrheal illness, shed the rotavirus in their stools, or demonstrated a seroresponse (Wyatt et al., in press). Kapikian et al. have evaluated orally administered RRV in 31 adults and 21 children with various levels of prevaccination serum neutralizing antibodies to RRV. The vaccine has not induced diarrheal illness in any of the volunteers. However, more than 80% of the vaccinees had a seroresponse to RRV, and approximately half of the vaccinees shed RRV as demonstrated in tissue culture inoculated with stool suspensions (Kapikian et al., in press ). Safety testing of RRV in children less than 2 years of age is currently in progress.
Another approach, the development of human-animal rotavirus reassortants as candidate vaccines, takes advantage of the well-known property of the reoviridae to undergo genetic reassortment after mixed infection in cell culture (3). This method was used previously for the cultivation of "noncultivatable" human rotaviruses with a temperaturesensitive (ts) mutant of bovine rotavirus as the "rescue" virus.
This report describes the development of reassortants between RRV or wild-type bovine rotavirus UK strain and each of three human rotavirus serotypes represented by the following strains: D (type 1), DS-1 (type 2), and P (type 3). These reassortants offer promise as potential vaccine candidates in that many contain 10 genes from the animal rotavirus parent and a single gene which codes for serotype specificity from the human rotavirus parent. They may well lack pathogenicity for humans because all but one of their genes are derived from an animal virus which appears to be attenuated for humans (Kapikian et al., in press; Wyatt et al., in press ). However, they should induce specific neutralizing antibodies to the human virus because they possess the gene which codes for human serotype specificity. Reassortment experiments. The stools containing the "noncultivatable" human rotavirus strains, D, DS-1, and P, were made into 10% suspensions and activated with trypsin (2 to 10 p.g/ml); the equivalent of 10 mg of stool was inoculated onto each AGMK cell monolayer of a six-well Costar tissue culture plate. The monolayers were centrifuged at 1,400 x g for approximately 60 min at 37°C. The cultures were washed once, and the animal rotavirus, also pretreated with trypsin (2 ,ug/ml), was inoculated onto the monolayer at a multiplicity of infection of ca. 1, and the cultures were incubated for 1 h at 37°C. The tissue monolayer was again washed and fed with Eagle minimal essential medium containing glutamine (2 mM), penicillin (250 U/ml), streptomycin (250 ,ug/ml), aureomycin (25 ,ug/ml), fungizone (2.5 ,ug/ml), and trypsin (0.5 pLg/ml). Inoculated cultures were then incubated for ca. 36 h at 37°C. Under the culture conditions employed in these studies, the human rotaviruses D, DS-1, and P did not form progeny detectable by plaque assay. Selection for the desired viral reassortants was achieved by exposing the progeny of the coinfected cultures to monoclonal antibodies or hyperimmune antiserum which specifically neutralized the animal rotavirus parent. Guinea pig hyperimmune antiserum prepared against the NCDV strain of bovine rotavirus, as previously described, was used to neutralize the bovine rotavirus UK strain and reassortants bearing the VP7 of the UK strain (3 fluid and directed at the neutralization protein, VP7, of RRV, was used to select against the RRV animal rotavirus parent and reassortants bearing the VP7 of RRV. These monoclonal antibodies immunoprecipitate the 38,000-dalton glycoprotein VP7 of RRV and specifically neutralize viruses belonging to serotype 3 (5) . The use of antiserum that neutralized VP7 but not VP3 of bovine rotavirus UK strain and the use of monoclonal antibodies directed at VP7 but not VP3 of RRV may have facilitated the isolation of reassortants as described below. The coinfection growth yield was incubated with the appropriate antiserum or monoclonal antibody ascites mixture diluted 1:100 before being inoculated onto the AGMK cell monolayers. In addition, the antiserum or monoclonal antibody mixture was added to the agarose overlay at a dilution of 1:1,000. The antiserum and the monoclonal antibody pool had neutralization titers (reciprocal) of 40,960 and greater than 81,920, respectively, against the homologous virus. After 4 to 5 days of incubation at 37°C, plaques were picked and these clonal populations were subjected to two further plaque purifications in AGMK cell monolayers. Neutralizing antiserum or a monoclonal antibody mixture was used in the first but not in the second of the two subsequent plaque purifications.
PRNA. The serotype of selected reassortants was determined by plaque reduction neutralization assay (PRNA) as described previously (17) . The neutralization titer of a serum to a given virus was defined as the reciprocal of the highest dilution of serum that produced 60% plaque reduction. If the titer fell between two dilutions, the Reed-Muench method was used for calculation.
RNA preparation. RNAs from the reassortant rotaviruses and from each of the parental rotaviruses were used to determine genotype by RNA hybridization. Each reassortant was grown in MA 104 cell monolayers in 2 to 3 wells of a six-well Costar plate. When maximum cytopathic effect was noted, the contents of the wells were pooled and centrifuged at 12,000 x g, and the pellet was extracted with chloroform-phenol to obtain genomic RNAs (9) . Parental virion RNAs were prepared by growing a large suspension of wild-type UK bovine rotavirus, RRV, or cultivatable human rotavirus strain DS-1 or P. The crude cell culture fluid was centrifuged at 82,500 x g, and the pellet was resuspended in phosphate-buffered saline. The pellet was then fluorocarbon extracted, and the aqueous phase was pelleted through a 30% sucrose cushion at 155,000 x g. Genomic RNAs were obtained from the pellet by chloroform-phenol extraction. Genomic RNAs were purified from rotavirus D strain by fluorocarbon extraction of a stool from an experimentally infected calf. This material was then pelleted through a sucrose cushion and extracted with chloroform-phenol. 32p_ labeled single-stranded RNAs were transcribed from viral cores of each of the parental rotaviruses by the method described by Flores et al. (2) , except that newly synthesized transcripts were precipitated with 2 M lithium chloride. Labeled transcripts were stored at -70°C until used.
Genotyping by RNA hybridization. Hybridization of cold, denatured double-stranded viral RNAs to the 32P-labeled single-stranded RNA probes was performed by the method of Kalica et al. (8) . RNAs were subjected to electrophoresis in polyacrylamide gel by the method of Laemmli (12) . Polyacrylamide gels (10%) were used routinely, and the duration of electrophoresis was ca. 14 h at 20 mA. UK, P, and RRV gene segments 7, 8, and 9 and D gene segments 7 and 8 were extremely difficult to resolve under these conditions. RESULTS
Wild-type bovine rotavirus (UK strain) x human rotavirus (D, DS-1, or P strain) reassortants. Under the selective pressure of bovine rotavirus NCDV antiserum, 24 bovine rotavirus (UK strain) x human rotavirus (D, DS-1, or P strain) reassortants were isolated ( Table 1) . Examination of the genotype of these reassortants by RNA-RNA hybridization revealed that 16 of the reassortants derived 10 gene Fig.  1 . These reassortants were were found to be similar if not identical to DS-1 virus, our prototype serotype 2 virus, and P, our prototype serotype 3 virus, respectively (Table 2) . These results indicate that the eighth gene segment of human rotavirus DS-1 strain is associated with serotype specificity, (6-1-1 ) and DS-1 x RRV (240-2-1) (the latter described in Fig. 2 (13) .
DISCUSSION
Arnalysis of the reassortants generated in this study reveals a distribution of genotypes that differs from that observed for reassortants derived from crosses between a ts mutant of bovine rotavirus UK strain and a "noncultivatable" human rotavirus strain W, Wa, or DS-1 (Table 1 ). In the latter situation, the non-ts human rotavirus parent usually contributes three or more genes to each reassortant (3, 4, 6, 10) . In contrast, the reassortants derived from a cross between a wild-type animal rotavirus and a "noncultivatable" human rotavirus frequently (57%) received only one gene from the human rotavirus parent. When a ts animal rotavirus was used for production of reassortants with human serotype, we provided selection against the neutralization antigen of the animal rotavirus by incubation with specific antibodies directed at this antigen. We also selected against the ts genes of the animal rotavirus parent by incubation of the coinfection growth yield at a temperature restrictive for the ts virus parent. In addition, silent mutations in other genes of'the mutagenized ts animal rotavirus parent may have been responsible for selection against these genes during incubation. When neither rotavirus parent was a ts mutant, as in the current study, selection against animal rotavirus genes was provided only by antibodies directed against the gene coding for the neutralization protein of the animal rotavirus parent.
One benefit of using a wild-type animal rotavirus instead of a ts animal rotavirus mutant in preparing reassortants for vaccine purposes is that the former has not been exposed to chemical mutagenesis. Thus First of all, monoclonal antibodies directed at VP3 of RRV neutralize RRV to a high titer when they are amplified in mouse ascites fluid as described by Greenberg et al. (5) . Wyatt and Hoshino made the observation that NCDV antiserum is highly reactive with VP7 of UK but not with VP3 of UK, whereas UK antiserum has antibodies directed against both VP3 and VP7. In summary, the single human rotavirus gene substitution reassortants described in this study exhibit the serotype specificity of their human rotavirus parent strains. However, they derive their minor neutralization protein, most likely VP3, from their animal rotavirus parent. This accounts for the low level of neutralization observed when the bovine-human rotavirus reassortants were tested with UK antiserum but not with NCDV antiserum, even though UK and NCDV rotaviruses belong to the same serotype; it also accounts for the low level of neutralization found when the RRV-human reassortants were tested with RRV antiserum but not with P antiserum, even though RRV and P rotaviruses are serotypically identical. In a recent publication, Hoshino et al. have observed some one-way antigenic relationships among certain rotaviruses and suggest that VP3 may play a role in this phenomenon (7) .
The single human rotavirus gene substitution reassortants described in this study represent potential vaccine candidates. The major neutralization protein of these reassortants is derived from the human rotavirus parent, and these viruses should therefore have the desired immunogenicity. It is also likely that the presence of 10 animal rotavirus genes in these reassortants will render such viruses attenuated for humans. This latter supposition is supported by the fact that bovine rotavirus UK and RRV have been administered to susceptible volunteers with a low level of serum antibodies and did not produce illness (Kapikian et al., in press; Wyatt et al., in press). These findings suggest that single human rotavirus gene substitution reassortants may be promising vaccine candidates for use in prevention of human rotavirus disease. The ability of these reassortants to grow in diploid cells may represent an additional advantage in production of vaccine virus because the diploid cell strain DBS-FRhL-2 appears to be free of adventitious agents, in contrast to AGMK cells, which must be carefully screened for endogenous viral contamination.
